<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464698</url>
  </required_header>
  <id_info>
    <org_study_id>2005-P-002159</org_study_id>
    <secondary_id>FIJ-MC-1003</secondary_id>
    <nct_id>NCT00464698</nct_id>
  </id_info>
  <brief_title>Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)</brief_title>
  <acronym>FIJ-MC-1003</acronym>
  <official_title>Duloxetine for the Treatment of Obsessive Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Duloxetine in the treatment of
      obsessive compulsive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obsessive compulsive disorder affects approximately 3% of the population. Treatment options
      include the selective serotonin reuptake inhibitors (SSRIs), dual serotonin and
      norepinephrine reuptake inhibitors (SNRIs), and behavioral therapy. Duloxetine is a new SNRI.
      This study aims to assess the efficacy of duloxetine for the treatment of OCD.

      Before subjects give written informed consent, they are made aware of alternatives to
      participation in this study, which can include independently seeking pharmacotherapy or
      cognitive behavioral treatment for OCD. Patients will then begin open-label treatment with
      duloxetine at 30 mg/day and will be seen again in one week (Visit 2). At Visit 2, patients
      will be assessed and, if they are not experiencing any significant side effects, the dose
      will be increased to 60 mg/day. Patients who are experiencing significant side effects at 30
      mg/day will be discontinued from the study and offered standard treatment in our clinic.
      Patients taking 60 mg/day will then return for assessment in four weeks (Visit 3). At this
      time, if they are not experiencing any significant side effects, the dose will then be
      increased to 120 mg/day. Patients who are unable to tolerate 120 mg/day will have their dose
      decreased back down to 60 mg/day and will continue the trial. End of study final statistical
      analyses will be conducted both including and excluding these patients. Remaining assessments
      will be every 4 weeks (Visits 4, 5, 6). Thus, in total this is a 17-week study with 12 weeks
      at the high dose believed to be necessary for response.

      At each visit following the initial visit, patients will be assessed using the Y-BOCS, BDI,
      BAI, and CGI. The Q-LES-Q will only be administered at the initial and last visit.

      The study procedure is similar to standard medical treatment for OCD at MGH. Like standard
      care, participants start on the lowest dose of the medication and then increase that dose to
      the maximally tolerated level. Barring any significant side effects, the patient remains on
      that dose for 4-8 weeks to provide the medication with an adequate trial period. At the end
      of that period, efficacy would be assessed and other alternatives would be discussed.

      One difference between the study and standard care is that the study will provide more
      assessment through verbal and written scales. This additional assessment could greatly
      benefit the patient as they decide between other treatment options. Another difference is
      that participants cannot be involved in current behavior therapy throughout the study. Many
      patients choose to pursue medical treatment without behavior therapy in standard care;
      however, in standard care, they have the option of pursuing both concurrently or pursuing
      just behavior therapy. If a patient wishes to pursue just behavior therapy or receive
      medication and therapy concurrently, then other forms of treatment at MGH might be more
      appropriate. If they only want medical treatment, the study is similar to standard care at a
      lower cost.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Y-BOCS Scores at 1st and Last Visit</measure>
    <time_frame>Week 0 to 17</time_frame>
    <description>OCD symptom change. This is the intention-to-treat analyses (with all 20 subjects included) rather than just the subjects who completed the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BDI (Beck Depression Inventory) - First and Last Visit (Week 0 and Week 17).</measure>
    <time_frame>Week 0 to 17</time_frame>
    <description>Depression severity, such that higher scores on the BDI are reflective of more severe depression.
BDI minimum score: 0 MDI maximum score: 63</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAI (Beck Anxiety Inventory) - First and Last Visit (Week 0 and Week 17)</measure>
    <time_frame>Week 0 to 17</time_frame>
    <description>Anxiety severity, such that a higher score on the BAI reflects more severe anxiety.
Minimum value: 0 Maximum value: 63</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLESQ (Quality of Life, Enjoyment, and Satisfaction Questionnaire) - First and Last Visit (Week 0 and Week 17)</measure>
    <time_frame>Week 0 to 17</time_frame>
    <description>Quality of life, such that lower score reflects poorer quality of life
Minimum score: 16 Maximum score: 80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Scale at Week 3 and Week 17</measure>
    <time_frame>Week 3 to 17</time_frame>
    <description>Global severity of illness, such that a higher score reflects worse global severity
Minimum score: 2 Maximum score: 14</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>All Study Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 30mg: Dose level 1 (Week 1) Duloxetine 60mg: Dose level 2 (Wks 2-4) Duloxetine 120mg: Dose level 3 (Wks 3-7)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Participants received increasing amounts of Duloxetine for 7 weeks.</description>
    <arm_group_label>All Study Participants</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of OCD by DSM-IV

          -  Age 18-65

          -  Y-BOCS greater than 20

          -  Written informed consent

          -  Females of childbearing potential must have a negative serum or urinary beta-HCG test.

        Exclusion Criteria:

          -  Pregnant women or women of childbearing potential who are not using a medically
             accepted means of contraception.

          -  Patients who, in the investigator's judgment, pose a serious suicidal or homicidal
             risk.

          -  Serious or unstable medical illness including cardiovascular (including hypertension),
             hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease. Patients
             on anticoagulant therapy.

          -  History of seizure disorder

          -  Comorbid bipolar disorder, psychosis, organic mental disorder, or developmental
             disorder

          -  If there is a history of substance abuse, patients in remission at least 6 months.

          -  Currently being treated with behavioral therapy, specifically exposure and response
             prevention, for OCD.

          -  Other medications for medical disorders that may interfere with duloxetine

          -  Current major depression or prescribed an antidepressant for major depression within
             the past 12 months. We will assess depressive symptoms with the BDI throughout the
             course of the study in order to assess subsyndromal depressive symptoms and to assess
             for the emergence of depressive symptoms.

          -  Taken other psychotropic medication within 2 weeks of beginning the study (4 weeks for
             fluoxetine).

          -  More than 1 adequate trial (at least 10 weeks at maximally tolerated dose) with
             another SSRI in the past.

          -  Known hypersensitivity to duloxetine or any of the inactive ingredients.

          -  Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization or
             potential need to use an MAOI drug during the study or within 5 days of
             discontinuation of study drug.

          -  Patients with uncontrolled narrow-angle glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darin D Dougherty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2007</study_first_posted>
  <results_first_submitted>March 15, 2016</results_first_submitted>
  <results_first_submitted_qc>January 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2017</results_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Darin Dougherty</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>OCD</keyword>
  <keyword>Obsessive Compulsive Disorder</keyword>
  <keyword>Obsessions</keyword>
  <keyword>Compulsions</keyword>
  <keyword>Duloxetine</keyword>
  <keyword>Cymbalta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Duloxetine Week 1 dose: 30mg Duloxetine Weeks 2-4 dose: 60mg Duloxetine Weeks 5-17 dose: 120mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: 30 mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: 60 mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3: 120mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine</title>
          <description>Duloxetine: Week 1 dose: 30mg, Weeks 2-4 dose: 60mg, Weeks 5-17 dose: 120mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.90" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Age of OCD onset</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age of OCD onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.35" spread="10.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Yale-Brown Obsessive Compulsive Scale (YBOCS)</title>
          <description>Minimum score possible: 0 Maximum score possible: 40
Greater scores indicate higher symptom severity</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.45" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of illness</title>
          <description>Mean duration of OCD</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.80" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Y-BOCS Scores at 1st and Last Visit</title>
        <description>OCD symptom change. This is the intention-to-treat analyses (with all 20 subjects included) rather than just the subjects who completed the treatment.</description>
        <time_frame>Week 0 to 17</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>Duloxetine: Week 1 dose: 30mg, Weeks 2-4 dose: 60mg, Weeks 5-17 dose: 120mg</description>
          </group>
        </group_list>
        <measure>
          <title>Y-BOCS Scores at 1st and Last Visit</title>
          <description>OCD symptom change. This is the intention-to-treat analyses (with all 20 subjects included) rather than just the subjects who completed the treatment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline YBOCS score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.45" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final YBOCS score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.45" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BDI (Beck Depression Inventory) - First and Last Visit (Week 0 and Week 17).</title>
        <description>Depression severity, such that higher scores on the BDI are reflective of more severe depression.
BDI minimum score: 0 MDI maximum score: 63</description>
        <time_frame>Week 0 to 17</time_frame>
        <population>20 participants with OCD were enrolled in a 17-week, open label treatment trial with duloxetine.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>Duloxetine: Week 1 dose: 30mg, Weeks 2-4 dose: 60mg, Weeks 5-17 dose: 120mg</description>
          </group>
        </group_list>
        <measure>
          <title>BDI (Beck Depression Inventory) - First and Last Visit (Week 0 and Week 17).</title>
          <description>Depression severity, such that higher scores on the BDI are reflective of more severe depression.
BDI minimum score: 0 MDI maximum score: 63</description>
          <population>20 participants with OCD were enrolled in a 17-week, open label treatment trial with duloxetine.</population>
          <units>units on a self-report questionnaire</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline BDI (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" spread="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit BDI (Week 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BAI (Beck Anxiety Inventory) - First and Last Visit (Week 0 and Week 17)</title>
        <description>Anxiety severity, such that a higher score on the BAI reflects more severe anxiety.
Minimum value: 0 Maximum value: 63</description>
        <time_frame>Week 0 to 17</time_frame>
        <population>20 participants with OCD were enrolled in a 17-week, open label treatment trial with duloxetine.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>Duloxetine: Week 1 dose: 30mg, Weeks 2-4 dose: 60mg, Weeks 5-17 dose: 120mg</description>
          </group>
        </group_list>
        <measure>
          <title>BAI (Beck Anxiety Inventory) - First and Last Visit (Week 0 and Week 17)</title>
          <description>Anxiety severity, such that a higher score on the BAI reflects more severe anxiety.
Minimum value: 0 Maximum value: 63</description>
          <population>20 participants with OCD were enrolled in a 17-week, open label treatment trial with duloxetine.</population>
          <units>units on a self-report questionnaire</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline BAI (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.70" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit BAI (Week 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.75" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QLESQ (Quality of Life, Enjoyment, and Satisfaction Questionnaire) - First and Last Visit (Week 0 and Week 17)</title>
        <description>Quality of life, such that lower score reflects poorer quality of life
Minimum score: 16 Maximum score: 80</description>
        <time_frame>Week 0 to 17</time_frame>
        <population>20 participants with OCD were enrolled in a 17-week, open label treatment trial with duloxetine.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>Duloxetine: Week 1 dose: 30mg, Weeks 2-4 dose: 60mg, Weeks 5-17 dose: 120mg</description>
          </group>
        </group_list>
        <measure>
          <title>QLESQ (Quality of Life, Enjoyment, and Satisfaction Questionnaire) - First and Last Visit (Week 0 and Week 17)</title>
          <description>Quality of life, such that lower score reflects poorer quality of life
Minimum score: 16 Maximum score: 80</description>
          <population>20 participants with OCD were enrolled in a 17-week, open label treatment trial with duloxetine.</population>
          <units>units on a self-report questionnaire</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Q-LES-Q (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.14" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit Q-LES-Q (Week 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.55" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions Scale at Week 3 and Week 17</title>
        <description>Global severity of illness, such that a higher score reflects worse global severity
Minimum score: 2 Maximum score: 14</description>
        <time_frame>Week 3 to 17</time_frame>
        <population>20 participants with OCD were enrolled in a 17-week, open label treatment trial with duloxetine.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>Duloxetine: Week 1 dose: 30mg, Weeks 2-4 dose: 60mg, Weeks 5-17 dose: 120mg</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions Scale at Week 3 and Week 17</title>
          <description>Global severity of illness, such that a higher score reflects worse global severity
Minimum score: 2 Maximum score: 14</description>
          <population>20 participants with OCD were enrolled in a 17-week, open label treatment trial with duloxetine.</population>
          <units>units on a self-report questionnaire</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline CGI (Week 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit CGI (Week 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread=".923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine: Week 1 Dose: 30mg</title>
        </group>
        <group group_id="E2">
          <title>Duloxetine Weeks 2-4 Dose: 60mg</title>
        </group>
        <group group_id="E3">
          <title>Duloxetine Weeks 5-17 Dose: 120mg</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>sexual dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Darin D. Dougherty, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-6300</phone>
      <email>ddougherty@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

